ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Christina Brzezniak, DO

VCS Physicians

Christina Brzezniak, DO Headshot

Compassionate care is achieved when we combine our medical expertise with an unwavering responsibility, to treat others as we would want to be treated ourselves. The most fulfilling part of my day is found in the relationships that I build with my patients. I find it a privilege to be part of each and every patient's journey.

Work and Credentials:

Primary Location

Reston Office


Medical Oncologist

Board Certification

Medical Oncology, Hematology and Internal Medicine


Walter Reed National Military Medical Center (National Capital Consortium)


Dwight David Eisenhower Army Medical Center


Dwight David Eisenhower Army Medical Center

Medical School

Lake Erie College of Osteopathic Medicine


University at Buffalo

Special Interests

Management of All Cancers, with a special interest in Lung Cancer and Thoracic Oncology

Dr. Brzezniak is originally from upstate New York and attended the University at Buffalo. She went onto earn her medical degree from Lake Erie College of Osteopathic Medicine. She then joined the Army, completing her internal medical training at Dwight David Eisenhower Army Medical Center and fellowship through the John P. Murtha Cancer Center at Walter Reed National Military Medical Center. Her military career spans 11 years, stationed not only in the United States but in support of deployed troops overseas. She served as the Assistant Chief Hematology Oncology clinic at Water Reed National Military Medical Center and is board certified in Medical Oncology, Hematology, and Internal Medicine. She is an accomplished Oncologist in management of all malignancies, and offers a warm collaborative approach to the complex care of her patients. She has a special interest in immunotherapy and lung cancer as well as breast cancer and other malignancies.

Dr. Brzezniak takes great pride in caring for her patients with cutting edge and compassionate community care. She has been recognized as a Top Doctor in Northern Virginia Magazine. While serving in the Army, she was named as the Chief of Immuno-Oncology and Thoracic Oncology, helping to build the research program at the John P. Murtha Cancer Center. At Virginia Cancer Specialists, she also serves as the principal investigator on multiple lung cancer clinical trials. She is a member of the American Society of Clinical Oncology and a national clinical trials researcher. She has contributed to multiple research publications on lung cancer and other types of malignancies. In an effort to help eliminate barriers for the management of lung cancer in our community, Dr. Brzezniak has been asked to participate as a panel representative for the FDA.

Dr. Brzezniak is affiliated with HCA Reston Hospital and INOVA Loudoun Hospital.

Dr. Brzezniak enjoys spending time with her husband and three children and her dog, Max. Her leisure time is spent reading, drawing and baking.



Physician Publications

March 9, 2020

Recalcitrant small cell lung cancer: the argument for optimism.

Read More
July 1, 2019

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.

Read More
November 5, 2018

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.

Read More

More Publications by Christina Brzezniak, DO

April 17, 2017

RRx-001 protects against cisplatin-induced toxicities.

Read More
April 6, 2017

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome.

Read More
March 29, 2017

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

Read More
March 1, 2017

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.

Read More
February 5, 2017

Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma.

Read More
November 1, 2016

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Read More
September 19, 2016

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Read More
May 24, 2016

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Read More
April 24, 2016

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Read More
March 11, 2016

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Read More

Clinical Trials (2)

Clinical Trial 19054

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Clinical Trial 18282

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Primary Location

Reston Office Office

Reston Office

Learn More

Other Locations